IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy

Cytokine

Volumn 24, Issue 3, 2003, Pages 57-66

  Koten, J W ^a,b   Van Luyn, M J A ^c   Cadee J A ^b   Brouwer, L ^c   Hennink, W E ^b   Bijleveld, C ^a   Den Otter, W ^a,b,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d BCH   (Netherlands)

Author keywords

Biocompatibility; Dextran; Interleukin 2; Microspheres; Slow release system

Indexed keywords

DEXTRAN; INTERLEUKIN 2; MICROSPHERE; SCHIFF BASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL DEATH; CONTROLLED STUDY; EDEMA; HISTOCOMPATIBILITY COMPLEX; INFLAMMATION; MACROPHAGE; MALE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; TISSUE REACTION; VASODILATATION;

EID: 0142248878     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-4666(03)00267-9     Document Type: Article

References (25)

1. Maas R.A., Dullens H.F.J., De Jong W.H., Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res. 49:1989;7037-7040.
2. Maas R.A., Van Weering D.H.J., Dullens H.F.J., Den Otter W. Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother. 33:1991;389-394.
3. Balemans L.T.M., Steerenberg P.A., Koppenhagen F.J., Kremer B.H.A., De Mulder P.H.M., Claessen A.M.E., et al. PEG-IL-2 therapy of advanced cancer in the guinea pig Impact of the primary tumour and beneficial effect of cyclophosphamide . Int J Cancer. 58:1994;871-876.
4. Forni G., Giovarelli M., Santoni A. Lymphokine-activated tumor inhibition in vivo I. The local administration of interleukin 2 triggers non-reactive lymphocytes from tumor bearing mice to inhibit tumor growth . J Immunol. 134:1985;1305-1311.
5. Vaage J. Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res. 47:1987;4296-4298.
6. Den Otter W., Dobrowolski Z., Bugajski A., Papla B., Van der Meijden A.P.M., Koten J.W., et al. Intravesical IL-2 to treat T1 papillary bladder carcinoma: regression of marker lesions in 8 out of 10 patients. J Urol. 159:1998;1183-1186.
7. Huland E., Heinzer H., Huland H. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res. 19:1999;2679-2683.
8. Den Otter W., Hill F.W.G., Klein W.R., Koten J.W., Steerenberg P.A., De Mulder P.H.M., et al. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res. 13:1993;2453-2456.
9. Den Otter W., Hill F.W.G., Klein W.R., Koten J.W., Steerenberg P.A., De Mulder P.H.M., et al. Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother. 41:1995;10-14.
10. Ziekman P.G.P.M. Local low-dose IL-2 therapy of tumours in companion animals. Anticancer Res. 19:1999;2016.
11. Den Otter W., De Groot J.W., Bernsen M.R., Heintz A.P.M., Maas R., Hordijk G.J., et al. Optimal regimes for local IL-2 tumour therapy. Int J Cancer. 88:1996;400.
12. Cadée J.A., De Groot C.J., Jiskoot W., Den Otter W., Hennink W.E. Release of recombinant human interleukin-2 from dextran-based hydrogels. J Control Release. 78:2002;1-13.
13. Cadée J.A., Brouwer L.A., Den Otter W., Hennink W.E., Van Luyn M.J.A. A comparative biocompatibility study of microspheres based on cross-linked dextran or poly(lactic-co-glycolic)acid after subcutaneous injection in rats. J Biomed Mater Res. 56:2001;600-609.
14. De Groot C.J., Cadée J.A., Hennink W.E., Den Otter W. Therapeutic efficacy of IL-2 loaded hydrogels in a mouse tumor model. Int J Cancer. 98:2002;134-140.
15. Van Dijk-Wolthuis W.N.E., Tsang S.K.Y., Kettenes-van den Bosch J.J., Hennink W.E. A new class of polymerizable dextrans with hydrolysable groups: hydroxy-ethyl metacrylated dextran with and without oligolactate spacer. Polymer. 38:1997;6235-6242.
16. Stenekes R.J.H., Franssen O., Van Bommel E.M.G., Crommelin D.J.A., Hennink W.E. The preparation of dextran microspheres in an all-aqueous system: effect of the formulation parameters on particle characteristics. Pharm Res. 15:1998;557-561.
17. Van Dijk-Wolthuis W.N.E., Van Steenbergen M.J., Underberg W.J.M., Hennink W.E. Degradation kinetics of methacrylated dextrans in aqueous solution. J Pharm Sci. 86:1997;413-417.
18. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 313:1985;1485-1492.
19. Dunn C.J., Hardee M.M., Fidler S.F., Shield S.K., Chosay J.G. The inflammatory potential of IL-2: local induction of a specific chronic granulomatous lesion in mice. J Leukoc Biol. 60:1991;27-36.
20. De Mik H.J.I., Koten J.W., Maas R.A., Den Otter W. Tumour regression by IL-2 mediated stagnation of blood flow. In Vivo. 5:1991;679.
21. Espinoza-Delgado I., Bosco M.C., Musso T., Gusella G.A., Longo D.L., Varessio L. Interleukin-2 and human monocyte activation. J Leukoc Biol. 57:1995;13-19.
22. Wahl S.M., McCartney-Francis N., Hunt D.A., Smith P.D., Wahl L.M., Katona I.M. Monocyte interleukin-2 receptor gene expression and interleukin augmentation of microbiocidal activity. J Immunol. 139:1987;1342-1347.
23. Philip R. Cytolysis of tumor necrosis factor (TNF)-resistant tumor targets Differential cytotoxicity of monocytes activated by the interferons, IL-2 and TNF . J Immunol. 140:1988;1345-1349.
24. Folkman J., Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29:(Suppl 16):2002;15-18. [review].
25. Winkelhake J.L., Gauny S.S. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev. 42:1990;1-18.